News

New Preclinical Data of Masitinib for ALS Presented at 4 Scientific Meetings This Year

AB Science has been invited to present new preclinical studies on masitinib in the treatment of amyotrophic lateral sclerosis (ALS) at four international meetings this year. These were the main findings from the series of preclinical studies: Proof of concept data from the preclinical trials of masitinib showed that the investigational drug “targets…

ALS End-stage Brain Damage Isn’t Limited to Motor Neurons, Study Finds

Patients with amyotrophic lateral sclerosis (ALS) who have progressed to a stage in which they’ve lost all voluntary movements, including the ability to communicate, have damage in numerous brain regions and isn’t limited to motor neurons. The study, “Clinicopathological characteristics of patients with amyotrophic lateral sclerosis resulting in…

Researchers May Have Solved ALS Molecular Misfolding Mystery

Researchers have identified a factor that prevents SOD1 — a protein causing amyotrophic lateral sclerosis (ALS) in a proportion of patients — from misfolding. The finding may advance the development of new drug therapies to stop or slow progression of the disease. The study, “Endogenous macrophage migration inhibitory factor reduces the…

Masitinib Marketing Application for ALS Accepted by European Medicines Agency

AB Science recently announced that the European Medicines Agency (EMA) has accepted a conditional marketing authorization application for the tyrosine kinase inhibitor masitinib to treat amyotrophic lateral sclerosis (ALS). AB Science develops protein kinase inhibitors (PKIs), a class of targeted proteins that are key for signaling pathways within cells. It has been shown that blocking…